NovoCure Ltd. NVCR

BAAR, Switzerland, October 01, 2026--Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.

BAAR, Switzerland, October 01, 2026--Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open.

NovoCure has seen its share price move around in recent years, and the stock now trades at US$16.67, which raises a straightforward question for investors: Is that level supported by what the business is generating in sales today and what the market expects those sales to become over time? Over the past 5 years the share price has fallen 86.1%, which puts the current valuation debate squarely on whether the remaining market value still lines up with the revenue base. The business model...

NovoCure (NVCR) is back in focus after the company confirmed that long-serving director Timothy Scannell retired from its board on September 2, 2026, following five years of service. The modest 0.85% 1 day share price return and 3.22% 7 day share price return leave NovoCure trading at US$16.67. At the same time, a 27.06% year to date share price return and 28.23% 1 year total shareholder return contrast with a much weaker 5 year total shareholder return, suggesting recent momentum is building...

BAAR, Switzerland, September 02, 2026--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.

The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.

NovoCure (NVCR) drew fresh investor attention after raising its 2026 net revenue guidance to a range of US$710 million to US$725 million, following a quarter of record sales and active patient growth. See our latest analysis for NovoCure. The recent guidance upgrade and record quarter come after a sharp swing in sentiment around NovoCure, with the stock gaining 41.54% on a 3 month share price return and 46.59% on a 1 year total shareholder return. However, longer term total shareholder...

Moby summary of NovoCure Limited's Q2 2026 earnings call

Investors rewarded strong execution, improving profits and raised outlook.

Novocure Ltd (NASDAQ:NVCR) soared to a new 52-week high on Thursday as investors positioned their portfolios amid a higher growth outlook for full-year 2026, and ahead of the expected premarket approval for its brain therapy candidate. In intra-day trading, the stock climbed to a record high of $20.55 before trimming gains to end the session […]